Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

76 results
Display

Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea

Ahn SY, Son SK, Lee GH, Kim I, Cheong JW, Lee WS, Kim BS, Jo DY, Jung CW, Seong CM, Lee JH, Yuh YJ, Kim MK, Ryoo HM, Park MR, Cho SH, Kim HG, Zang DY, Park J, Kim H, Lee S, Kim SH, Chang MH, Lee HS, Choi CW, Kwon J, Lim SN, Oh SJ, Joo I, Kim DW

Background Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of imatinib administration on the mouse ovarian follicle count and levels of intra-ovarian proteins related to follicular quality

Kim SJ, Kim TE, Jee BC

Objective: The impact of imatinib, a tyrosine kinase inhibitor, on ovarian follicles and several proteins related to follicular function and apoptosis was investigated in mice. Methods: Saline, cyclophosphamide (Cp; 50 or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review

Yoon JH, Hong AR, Kim HK, Kang HC

Lenvatinib prolongs the survival of patients with advanced thyroid cancer. At initiation of lenvatinib therapy, advanced thyroid cancer patients frequently have lung metastasis and are vulnerable to pulmonary complications due...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

Ahn JS, Kim HJ

FMS-like tyrosine kinase 3 (FLT3) mutations, the most frequently detected genetic aberrations in patients with acute myeloid leukemia (AML), are identified in approximately 30% of patients with newly diagnosed AML...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Huang YH, Hsu KH, Chin CS, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJ, Chang GC

Purpose The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. Materials and Methods From...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia

Kim MJ

Tyrosine kinase inhibitors (TKIs) are targeted therapy drugs that selectively inhibit protein kinases. Nephrotoxicity associated with TKIs is uncommon. We report a case of a 39-year-old man with acute kidney...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-thrombotic ischemic cerebrovascular events related to the use of tyrosine kinase inhibitors in patients with cancer: high-resolution magnetic resonance imaging findings

Sim JE, Park J, Bang OY

The targeted cancer therapies that have been introduced in recent years are directed against cancer-specific molecules and signaling pathways, and thus, they have limited nonspecific toxicities. However, major vascular events,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer

Shong YK

Radioiodine refractory differentiated thyroid cancers are rare but they make a definite problem since they run relentlessly progressive course leading to death in a few years. Recent development of various...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia

Kim Y, Go TH, Jang J, Lee JB, Lim ST, Shim KY, Lee JI, Kong JH

Background/Aims: Adherence to tyrosine kinase inhibitors (TKIs) has become a critical aspect of care in chronic myeloid leukemia (CML). We aimed to examine the association of TKI adherence with overall...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Retrospective evaluation of toceranib phosphate (Palladia) for treatment of different tumor types in 31 dogs

Choi SI, Nam YL, Kim JK, Park HJ, Song KH, Seo KW

The purpose of this retrospective study was to provide additional data on the use of toceranib in a wide variety of tumor types in small breed dogs, especially < 8...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey

Uhm J, Kim KH, Lee H, Kim H, Cassandra S, Joo I, Jung CW

Background: The global TARGET survey examined real-world management of chronic myeloid leukemia (CML) compared with international guideline recommendations. This report focused on the responses of physicians from South Korea compared...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis

Lin Y, Lin M, Zhang J, Wang B, Tao Z, Du Y, Zhang S, Cao J, Wang L, Hu X

Purpose Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy

Goh MJ, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW

Transarterial radioembolization (TARE) with yttrium-90 microspheres has become widely utilized in managing hepatocellular carcinoma (HCC). The utility of TARE is expanding with new insights through experiences from real-world practice and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP

Purpose Triple-negative breast cancer (TNBC) is highly malignant and has poor prognosis and a high mortality rate. The lack of effective therapy has spurred our investigation of new targets for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Information Consistency of Clinically Significant Drug Interactions in Tyrosine Kinase Inhibitors

An S, Lee JY, Ah YM

Background: Drug-drug interactions (DDIs) in patients using oral anticancer treatment are more common than in those using injectable anticancer agents. In addition, DDIs related to anticancer treatment are known to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review

Lim DH, Yoon JH, Jun DW, Lee OY, Yoon BC, Lee HR, Kim KS, Choi HS

Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

Hwang HS, Park YY, Shin SJ, Go H, Park JM, Yoon SY, Lee JL, Cho YM

BACKGROUND: Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully evaluated. METHODS: We performed gene expression profiling on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JCH, Mitsudomi , Lee JS

Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors

Han JM, Gwak HS

BACKGROUND: Small-molecule tyrosine kinase inhibitors (TKIs) have had major impacts on anticancer therapy by targeting the catalytic activities of dysregulated tyrosine kinases. TKIs have not presented traditional toxicities; however, some...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr